

2 BRAND-NEW CANNABIS TRADING TOOLS

TO UTILIZE ON
ROBINHOOD TODAY



2 Brand-New Cannabis Trading Tools to Utilize on Robinhood Today

Trading services are battling it out to win over more clients, and that ultimately benefits investors just like you.

Robinhood is a perfect example.

Founded in 2013, Robinhood has made a name for itself because of its easy-to-use format, commission-free trades, and cash-management services.

And now, it's offering investors two new tools to utilize: Fractional investing and dividend reinvestment programs (DRIPs). With fractional investing, you can buy as little as \$1 worth of stock.

If you enroll a stock in a DRIP, instead of cashing out a dividend payout, you can use it to buy more shares of the stock for free.

A few of the companies that many of our members own, like **Innovative Industrial Properties Inc.** (NYSE: [IIPR](#)), **Scotts-Miracle Gro Company** (NYSE: [SMG](#)), and **Constellation Brands** (NYSE: [STZ](#)), offer fractional investing and DRIPs.

So today, the *National Institute for Cannabis Investors* is going to give you all the details on how to utilize these investing tools as a part of your investing strategy.

Let's start with fractional investing.

Fractional Investing on Robinhood

We know that many of you have a “\$25 Plan” when it comes to cannabis investing, which involves buying a few shares of cannabis stocks each week and spending a total of \$25.

Well, now you can buy \$25 of stock each week in individual companies no matter how much the stock is trading for!

You may really like Constellation Brands but don't want to pay \$169 for just one share. Well, now you can invest as little as \$1, and you will receive a fraction of STZ shares.

You could also buy \$25 worth of STZ.

Or \$50 worth of STZ.

Or \$100 worth of STZ.


It's also simple to get started.

Let's stick with Constellation Brands as an example.

When you click on the “Trade” button, the option to buy the stock will appear.

Click “Buy.”

Then, when it asks you for the number of shares that you want to buy, you can type in the fractional amount. For instance, if you wanted to buy \$50 worth of Constellation Brands at \$169.42 per share, you would enter 0.30 for the number of shares.



Number of Shares 0.30
Market Price ⬆️ \$169.42
Estimated Cost \$50.83
Review
1 2 3
4 5 6
7 8 9
. 0 <⌂>

So whether you wanted to invest \$1 or \$100 a week, you now have that option on Robinhood.

It's a great way to stick to a budget while also being able to buy into the high-growth cannabis industry.

Next, let's take a look at DRIPs.

Dividend Reinvestment Programs on Robinhood

Utilizing a DRIP is a great strategy to receive more shares of a company without having to pay any additional money.

Here's how it works.

Some investors treat dividends as income payments, which is perfectly fine. Each quarter, when a company pays dividends to its shareholders, some investors will take that money out of their trading account and put it into their bank account.

However, with a DRIP, you can use that dividend payment to buy more shares of a stock without having to invest more money. That dividend payment is simply used to buy shares of the company, and it doesn't matter if the dividend payment is less than what the stock price is trading for.

A DRIP will buy fractional shares.

If you believe in the long-term outlook of the company, continually having more shares added to your account can really add up over time.

Conclusion

As part of a cannabis investing strategy, fractional investing and DRIPs are great tools to utilize.

At the *National Institute for Cannabis Investors*, we also have what we call the “Vault,” which is one of the most comprehensive cannabis databases in the world.

From ETFs to penny stocks, we currently have over 300 entries in the database.

As we analyze each company, we provide ratings on a simple scale from 0–5.

You can learn more about the “Vault” [right here](#).

To your investing success,

The Institute

PLEASE NOTE

From time to time, the National Institute for Cannabis Investors, LLC will recommend stocks or other investments that will not be included in our regular portfolios. There are certain situations where we feel a company may be an extraordinary value but may not necessarily fit within the selection guidelines of these existing portfolios. In these cases, the recommendations are speculative and should not be considered as part of the National Institute for Cannabis Investors, LLC philosophy.

Also, by the time you receive this report, there is a chance that we may have exited a recommendation previously included in our portfolio. Occasionally, this happens because we use a disciplined selling strategy with our investments, meaning that if a company's share price falls below a certain price level, we immediately notify our subscribers to sell the stock.

NOTE: National Institute for Cannabis Investors, LLC is not a broker, dealer or licensed investment advisor. No person listed here should be considered as permitted to engage in rendering personalized investment, legal or other professional advice as an agent of National Institute for Cannabis Investors, LLC. National Institute for Cannabis Investors, LLC does not receive any compensation for these services. Additionally, any individual services rendered to subscribers by those mentioned are considered completely separate from and outside the scope of services offered by National Institute for Cannabis Investors, LLC. Therefore if you choose to contact anyone listed here, such contact, as well as any resulting relationship, is strictly between you and them.

II NATIONAL INSTITUTE *for* **CANNABIS INVESTORS**

**Copyright 2007-Present National Institute for Cannabis Investors, LLC
1125 N. Charles Street, Baltimore, MD 21201 Phone: 866.260.0361**

All rights reserved. National Institute for Cannabis Investors, LLC provides its members with unique opportunities to build and protect wealth, globally, under all market conditions. The executive staff, research department and editors who contribute to National Institute for Cannabis Investors, LLC recommendations are proud of our history and reputation. We believe the advice presented to our subscribers in our published resources and at our meetings and seminars is the best and most useful available to global investors today. The recommendations and analysis presented to members is for the exclusive use of members. Copying or disseminating any information published by National Institute for Cannabis Investors, LLC, electronic or otherwise, is strictly prohibited. Members should be aware that investment markets have inherent risks and there can be no guarantee of future profits. Likewise, past performance does not assure future results. Recommendations are subject to change at any time, so members are encouraged to make regular use of the website and pay special attention to National Institute for Cannabis Investors, LLC updates sent out via e-mail. The publishers, editors, employees or agents are not responsible for errors and/or omissions.

PRIVACY NOTICE

You and your family are entitled to review and act on any recommendations made in this document. All National Institute for Cannabis Investors, LLC publications are protected by copyright. No part of this report may be reproduced by any means (including facsimile) or placed on any electronic medium without written permission from the publisher. Information contained herein is obtained from sources believed to be reliable, but its accuracy cannot be guaranteed. National Institute for Cannabis Investors, LLC expressly forbids its writers from having a financial interest in any security recommended to its readers. All National Institute for Cannabis Investors, LLC employees and agents must wait 24 hours after an Internet publication and 72 hours after a print publication is mailed prior to following an initial recommendation. National Institute for Cannabis Investors, LLC does not act as a personal investment advisor, nor does it advocate the purchase or sale of any security or investment for any specific individual. Investments recommended in this publication should be made only after consulting with your investment advisor, and only after reviewing the prospectus or financial statements of the company.